




A**B****C**

Supplemental Figure legend

Supplemental Fig. 1. Supporting Material. (A) Symptoms related to SARS-CoV-2 infection. Each row represents a (type of) symptoms and expresses the percentage of study subjects who self-reported that symptom(s). The study subjects reported different numbers/types of symptoms, therefore the total number of the symptoms reported exceeds the number of study subjects. **(B) Titers of circulating anti-RBD IgG antibodies.** Trajectories of RBD-specific IgG antibody titers corresponding to the OD405 data shown in main Fig. 1A. Study subjects and definition of sustainers and decayers are as per Fig. 1A. **(C) Method for neutralizing titer 50 (NT50) determination.** Representative neutralization curves are shown to show the determination of 50% neutralization (red dotted line) for the calculation of the NT50 values presented in Main Fig. 1 and Fig. 3. Relative infection rates, shown in the Y axis of the scatter plot, were calculated as in the legend to main Fig. 1. The light green line curve corresponds to an uninfected (negative control) sample exhibiting no neutralizing activity.

Table 1. Characteristics of study participants

Characteristics	n=83
Age (years), median (IQR*)	45 (31-56)
Gender, n (%)	
Male	38 (46)
Female	45 (54)
Race, n (%)	
African American or Black	6 (7)
Alaskan Native of American Indian	0 (0)
Asian or Pacific Islander	13 (16)
White	63 (76)
Other	1 (1)
Ethnicity, n (%)	
Hispanic or Latino	16 (19)
Non-Hispanic	67 (81)
SARS-CoV-2 PCR Positivity, n (%)	
Positive	81 (98)
Negative	0 (0)
Not performed**	2 (2)
Peak Disease Severity, n (%) [Female (F), Male (M)]	
Asymptomatic	1 (1) [0F, 1M]
Mild (Non-hospitalized; 1-4 symptoms)	55 (66) [30F, 25M]
Moderate (Non-hospitalized; 5 or more symptoms)	22 (27) [16F, 6M]
Severe (Hospitalized)	5 (6) [2F, 3M]
Days After Symptom Onset at Initial Collection (n=82***), median (IQR*)	34 (26-42)

*Interquartile range.

**Subjects who did not receive the PCR test were diagnosed by exposure history (PCR-positive household members), COVID-19 symptoms, and positive chest x-ray findings.

***The asymptomatic subject was not included.

Table 2. Characteristics of study subjects followed longitudinally

Characteristics	n=23
Age (years), median (IQR*)	39 (31-56)
Gender, n (%)	
Male	9 (39)
Female	14 (61)
Race, n (%)	
African American or Black	2 (9)
Alaskan Native of American Indian	0 (0)
Asian or Pacific Islander	3 (13)
White	18 (78)
Ethnicity, n (%)	
Hispanic or Latino	6 (26)
Non-Hispanic	17 (74)
SARS-CoV-2 PCR Positivity, n (%)	
Positive	21 (91)
Negative	0 (0)
Not performed**	2 (9)
Peak Disease Severity, n (%) [Female (F), Male (M)]	
Asymptomatic	1 (4) [0F, 1M]
Mild (Non-hospitalized; 1-4 symptoms)	15 (65) [6F, 9M]
Moderate (Non-hospitalized; 5 or more symptoms)	7 (31) [5F, 2M]
Severe (Hospitalized)	0 (0) [0F, 0M]
Days After Symptom Onset at Initial Collection (n=22***), median (IQR*)	38.5 (26-42)

*Interquartile range.

**Subjects who did not receive the PCR test were diagnosed by exposure history (PCR-positive household members), COVID-19 symptoms, and positive chest x-ray findings.

***The asymptomatic subject was not included.

Table S3. Comparison of cell subsets in non-infected and infected subjects

Cell subset	Phenotype	A, Non-infected	B, Infected <2m post	C, Infected >5m post	p value	
					A vs. B ⁱ	B vs. C ⁱⁱ
Total B Cell	CD19 ⁺ CD20 ⁺	9.6 (7.0-12.0)	6.0 (4.0-10.7)	6.4 (4.8-8.1)	0.08	0.36
PB	CD38 ^{hi} CD27 ⁺	0.4 (0.2 - 0.7)	1.1 (0.4-1.6)	0.37 (0.2-0.9)	0.01	0.04
Non-PB	CD38 ^{lo}	64.5 (47.1-65.9)	51.2 (41.7-59.6)	56.6 (49.5-65.8)	0.03	0.005
Naïve	CD27 ⁻ IgD ⁺	55(42.2-59.7)	34.9(25.9-34.8)	30.2(18.1-35.8)	0.0004	0.04
NSM	CD27 ⁺ IgD ⁺	11 (6.9-16.2)	12.1 (7.0-18.3)	9.7 (2.8-14.6)	0.27	0.04
SM	CD27 ⁺ IgD ⁻	23.4 (21.3-29.3)	36.2 (26.6-51.6)	35 (28.2-43.5)	0.006	0.25
SM IgM ⁺	CD27 ⁺ IgD ⁻ IgM ⁺	14.9 (9.2-22.3)	4.3(3.5-5.9)	10.1(7.7-17.3)	0.001	<0.0001
SM IgG ⁺	CD27 ⁺ IgD ⁻ IgG ⁺	6.7 (2.0-8.0)	4.3(3.5-5.9)	7.7(2.7-14.9)	0.21	0.04
DNM	CD27 ⁻ IgD ⁻	7.9(5.0-12.5)	10.4 (7.5-16.4)	21.3 (12.2-34.6)	0.08	0.003
RBD ⁺ B Cell	CD19 ⁺ CD20 ⁺ RBD ⁺	ND	1.13 (0.88-1.36)	1.03 (0.8-1.62)	NA	0.08
RBD ⁺ Naïve	RBD ⁺ CD27 ⁻ IgD ⁺	ND	50.9(40.6-68.7)	50 (43.3-62.0)	NA	0.30
RBD ⁺ NSM	RBD ⁺ CD27 ⁺ IgD ⁺	ND	5.4 (3.3-14.3)	8.6 (5.3-14.2)	NA	0.4
RBD ⁺ SM	RBD ⁺ CD27 ⁺ IgD ⁻	ND	27.1(14.1-39.3)	21.4(13.2-35.6)	NA	0.42
RBD ⁺ DNM	RBD ⁺ CD27 ⁻ IgD ⁻	ND	7.4 (4.4-11.1)	11.8(6.5)-18.2	NA	0.01

Data are presented as median and interquartile range (IQR); PB - Plasmablast; NSM - non switched memory; SM - switched memory;

DNM - double-negative memory

ⁱComparison between non-infected and infected (<2 months) using Mann-Whitney U test

ⁱⁱComparison between infected (<2 months) and infected (>5 months) using Wilcoxon matched pairs test

ND, Non detected

NA, Not applicable

Table S4. Comparison of cell subsets in pre- and post-vaccinations of non-infected and infected subjects

Cell subset	Phenotype	A, Infected, pre-vac	B, Infected, post-vac	C, Non-infected, pre-vac	D, Non-infected, post-vac	p value	
						A vs. B ⁱ	C vs. D ⁱⁱ
B Cell	CD19 ⁺ CD20 ⁺	5.1 (3.3-7.2)	3.5 (2.2 -4.7)	12.25 (11.5-16.7)	4.3 (3.2-4.8)	0.03	0.004
RBD ⁺ B Cell	CD19 ⁺ CD20 ⁺ RBD ⁺	0.5 (0.3-0.8)	1.1 (0.9-1.6)	ND	0.8 (0.5-0.9)	0.003	0.004
PB	CD38 ^{hi} CD27 ⁺	0.6 (0.1-1.1)	0.4 (0-1.2)	0.4 (0.06-0.9)	0.2 (0.2-0.6)	0.31	0.34
Non-PB	CD38 ^{lo}	59.8(48.4 -66)	58(52.8-62.8)	66.3 (63.3-69.4)	62.1 (58.4-65)	0.42	0.02
Naïve	CD27 ⁻ IgD ⁺	25.8 (12.5-37.1)	63.3 (5.4-71.7)	57.7 (49.1-63.6)	66.5 (64.1-73.9)	0.002	0.01
NSM	CD27 ⁺ IgD ⁺	5.7(0.4-10.6)	3.5(2.7-9.3)	9.7(9.0-11.4)	5.4(3.7-8.9)	0.42	0.01
SM	CD27 ⁺ IgD ⁻	41.7 (25.1-49.7)	14.9 (12.5-17.7)	23.4 (20.2-30.6)	14.9 (12.5-17.7)	0.002	0.01
DNM	CD27 ⁻ IgD ⁻	19.2 (13.3-49.8)	14.7 (9.8-17.8)	9.9(2.9-10.6)	9.8(6.1-12.5)	0.007	0.27

Data are presented as median and interquartile range (IQR); PB - Plasmablast; NSM - non switched memory; SM - switched memory;

DNM - double negative memory; vac - vaccination

Comparisons of infected pre- vs post-vaccinationⁱ and non-infected pre- vs post-vaccinationⁱⁱ using Wilcoxon matched pairs test